55 patients with HIV-associated sensory neuropathy (HIV-SN) were randomly assigned to receive either one 0.9g cigarette (3.56% delta-9-tetrahydrocannabinol) per day for 5 days, or its respective placebo with the identical schedule. Patients were assessed on pain on Visual Analogue Scale (VAS), hyperanalgesia, pain to heat stimulation, and incidence and severity of adverse events daily for 12 days. Results showed that smoked cannabis was effective in reducing pain and hyperanalgesia, but had an insignificant effect on pain to heat stimulation. Despite eliciting greater severity of side effects than placebo, smoked cannabis did not raise any serious safety concerns.